 Orphan Drug Production
"Orphan Drug Production" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others.
| Descriptor ID |
D009965
|
| MeSH Number(s) |
J01.576.655.750.600
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Orphan Drug Production".
Below are MeSH descriptors whose meaning is more specific than "Orphan Drug Production".
This graph shows the total number of publications written about "Orphan Drug Production" by people in this website by year, and whether "Orphan Drug Production" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2019 | 2 | 0 | 2 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Orphan Drug Production" by people in Profiles.
-
Costa E, Girotti S, van den Ham HA, Cipolli M, van der Ent CK, Taylor-Cousar JL, Leufkens HGM. Traits, trends and hits of orphan drug designations in cystic fibrosis. J Cyst Fibros. 2023 09; 22(5):949-957.
-
Berry SA, Coughlin CR, McCandless S, McCarter R, Seminara J, Yudkoff M, LeMons C. Developing interactions with industry in rare diseases: lessons learned and continuing challenges. Genet Med. 2020 01; 22(1):219-226.
-
Karas L, Lu CY, Agrawal PB, Asgari MM. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers. J Am Acad Dermatol. 2019 09; 81(3):867-877.
-
Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care. 2015 Oct; 38(10):1975-85.
-
Gerardo CJ, Lavonas EJ, McKinney RE. Ethical considerations in design of a study to evaluate a US Food and Drug Administration-approved indication: antivenom versus placebo for copperhead envenomation. Clin Trials. 2014 Oct; 11(5):560-4.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|